What's Happening?
A recent clinical trial conducted by researchers at University College London (UCL) has found that two widely available medications, colchicine and a combination of antihistamines (famotidine and loratadine), provide modest short-term relief from fatigue
in individuals suffering from long COVID. The study, published in The Lancet Infectious Diseases, involved nearly 800 adults receiving care at specialized long-COVID clinics in England. Participants were randomly assigned to receive either their usual care or treatment with one of three drugs: colchicine, the antihistamine combination, or the blood thinner rivaroxaban. Over a 12-week period, the study observed improvements in fatigue across all groups, including those who did not receive any drug intervention. However, the improvements were not sustained beyond 24 weeks. The study highlights the potential of these drugs to address immune dysregulation linked to long COVID, though further research is needed to understand the mechanisms involved.
Why It's Important?
The findings of this study are significant as they contribute to the growing body of research aimed at identifying effective treatments for long COVID, a condition affecting an estimated 1% to 5% of adults worldwide. Long COVID presents a range of debilitating symptoms, including fatigue, muscle pain, and brain fog, for which there are currently no licensed treatments. The study's results suggest that while colchicine and antihistamines may offer temporary relief, they are unlikely to provide a long-term solution. This underscores the need for continued research into more effective treatments. The study also highlights the importance of addressing the healthcare gap in long-COVID care, as noted by Tiffany Walker, MD, in an accompanying commentary. The potential for these drugs to modulate immune responses could pave the way for new therapeutic strategies.
What's Next?
Further research is necessary to explore the mechanisms by which colchicine and antihistamines may alleviate symptoms of long COVID. The study's authors, including Amitava Banerjee, PhD, emphasize that these drugs alone are unlikely to be the definitive answer to long COVID fatigue. Future studies may focus on combining these medications with other treatments or exploring alternative therapies that target the underlying causes of long COVID. Additionally, healthcare providers and long-COVID care teams may consider these findings when developing treatment plans for patients, while remaining cautious about the limitations of these drugs' efficacy over the long term.
